Evidence map›Paper›PMID 41869397›Full record

ArticleInternational journal of nanomedicine2026

A Self-Assembling Nanomodulator for Synergistic Therapy of Intracerebral Hemorrhage.

Tian Yun, Dan Hou, Yujie Hu, Yonghao Fan, Shun Zhang, Tiantian Wu, Yong You

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tian Yun *Department of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Dan Hou *Department of neurology, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, Hainan, People's Republic of China.
Yujie HuDepartment of neurology, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, Hainan, People's Republic of China.
Yonghao FanDepartment of General Medicine, West China Lecheng Hospital of Sichuan University, Qionghai, Hainan, People's Republic of China.
Shun ZhangSchool of Pharmacy, Hainan Medical University, Haikou, Hainan, People's Republic of China.
Tiantian WuDepartment of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.ORCID 0009-0002-7515-7566
Yong YouDepartment of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Intracerebral hemorrhage (ICH) has high mortality and morbidity due to a complex secondary injury phase driven by oxidative stress and excessive inflammation. Given the limited efficacy of singularly-targeted therapies, there is a pressing need for novel therapeutic strategies capable of simultaneously modulating multiple aspects of this pathophysiological network. Methods: We developed a self-assembled nanomodulator, namely TNF@Gin: Targeted Nano Flower loaded with Ginkgetin (TNF@Gin), by fabricating Ginkgetin-loaded Nano Flowers via Rolling Circle Amplification (RCA). The therapeutic efficacy and mechanisms were systematically evaluated in microglial cells, hippocampal neuronal cells, and an ICH mouse model. Results: TNF@Gin demonstrated a synergistic regulatory effect by scavenging toxic reactive oxygen species, stimulating the polarization of microglia to the anti-inflammatory M2 phenotype, and inhibiting ferroptosis in hippocampal cells via the Nrf2/GPX4 pathway. In a mouse model of ICH, intravenous administration of TNF@Gin effectively alleviated brain hemorrhage and mitigated ICH-induced behavioral deficits. Conclusion: The nanomodulator TNF@Gin we developed is a safe and highly effective therapeutic agent for ICH synergistic therapy. To the best of our knowledge, this study represents the first RCA-based drug delivery system for ICH synergistic treatment, offering a novel and promising therapeutic strategy that synergistically targets inflammation and ferroptosis.

Indexed as

Cerebral HemorrhageTumor Necrosis Factor-alphaAnimalsDisease Models, AnimalDrug Delivery SystemsHippocampusHumansMaleMiceMice, Inbred C57BLMicrogliaOxidative StressReactive Oxygen SpeciesReactive Oxygen SpeciesTumor Necrosis Factor-alphabiomaterialsDNA nanotechnologyICH synergistic therapynanomedicine

Identifiers

PMID41869397
PMCPMC13004127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.